5 Healthcare Stocks to Buy Today According to Steven Cohen’s Point72 Asset Management

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Point72 Asset Management’s Holdings: $122 million

Percentage of Point72 Asset Management’s Portfolio: 0.49%

Number of Hedge Fund Holders: 35

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an Irish biopharmaceutical firm that develops several drugs to treat diseases in the United States and globally. These drugs cover sleep disorders, cancer, leukemia, liver diseases, and post traumatic stress disorder.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) raked in $896 million in revenue and $4.21 in non-GAAP EPS for its fiscal Q4, beating analyst estimates for both. 35 hedge funds owned a stake in the company as of December 31, with Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s largest investor among them being Jim Simons’ Renaissance Technologies, which owned 1.7 million shares worth $216 million.

Point72 Asset Management’s stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was worth $122 million by the end of December 2021, as the firm owned 963,824 shares. H.C. Wainwright raised its price target on JAZZ to $215 from $210 in March 2022, believing that the company’s strong quarterly results will carry forward throughout 2022.